October 19, 2014

HIV R4P roundup, funding updates, and more...

As the prevention research field’s first combined gathering, HIV R4P exemplifies the simple truth that ridding the world of HIV/AIDS will require a vaccine and other prevention methods, as well as treatment and a cure. Against a backdrop of increasing synergies — and a drop in prevention research funding — scientists and advocates will meet across disciplines to share latest results and explore new and enhanced collaborations
There will be important updates on the exciting advances in AIDS vaccine R&D — such as new knowledge about targets on HIV and antibody evolution that are accelerating immunogen design; vectors moving forward in preclinical studies; the advancement of new immunogens into testing and people; and developments in microbicides and pre-exposure prophylaxis that could impact future vaccine trials. Click here to read a great preview by conference co-chair and Imperial College London Professor Robin Shattock in the latest issue of IAVI Report.
In the satellite session Early Infection Cohorts: Insights for Design of Vaccines and Other Interventions, IAVI and the University of KwaZulu-Natal will gather representatives from major research organizations who will share valuable insights from studies of early HIV infection with longitudinal follow-up that have contributed in many ways to our understanding of the epidemic.
The satellite session Mind the Gaps: Economic, Structural and Human Dimensions of Access to AIDS Vaccines, and Their Importance for Decision Making in R&D, organized by IAVI, MHRP, HVTN, UNAIDS and amfAR, explores the interdependencies needed to ensure that future vaccines can quickly reach the people most in need. This critical issue is also the subject of the conference’s closing plenary, with speakers including Alex Coutinho, Director of the Infectious Diseases Institute in Kampala and IAVI Board Chair.
In Help End AIDS Together: Toward Vaccine and Cure for HIV/AIDS, leading researchers will discuss the increasing scientific convergences that may well produce both a vaccine and a cure. Also read a related commentary in Project Syndicate by IAVI President and CEO Margie McGlynn and Nobel Laureate Françoise Barré-Sinoussi.
During the Advocates' Pre-conference Workshop: Strengthening Advocacy for Research to Rollout, IAVI and partners GYCA and the ICASA YouthFront will launch the Talking Voices video campaign, exploring youth interaction with modern-day sex and prevention.
And IAVI, HVTN, NIAID and MHRP will also host a reception and photo exhibit celebrating the critical partnerships that will lead to a vaccine against HIV/AIDS.
In addition, IAVI and our partners will present on more than 50 topics ranging from the continuing insights into HIV’s natural progression that are guiding vaccine design, forecasts of the dramatic impact a vaccine could have on rates of HIV infection, details of India-specific broadly neutralizing antibodies, the challenges of electronic fingerprinting in Zambia, training of Kenyan health care providers who attend to men who have sex with men.  
Follow us on Twitter (@AIDSVaccine) and visit www.iavi.org/HIVR4P for reports from Cape Town.
Ending Epidemics Through Technology: Developing an HIV Vaccine is a discussion on the status of HIV vaccines and how the US will need to change its response to the global epidemic. Featuring: Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases (NIAID), Margie McGlynn, IAVI President and CEO, and Mitchell Warren, Executive Director of AVAC. At the Center for Strategic and International Studies, 1616 Rhode Island Ave., NW, Washington, DC 20036.
IAVI recently received several grants from US-based foundations of the kind of unrestricted funding that helps to foster scientific innovation: Broadway Cares/Equity Fights AIDS increased their annual grant, VWR Foundation renewed their funding, and the Keith Haring Foundation made a first-time grant. Additionally, an award from the Korean Women against AIDS marked the first gift to IAVI from Korea.